Literature DB >> 8821303

Upregulation of IgE synthesis by staphylococcal toxic shock syndrome toxin-1 in peripheral blood mononuclear cells from patients with atopic dermatitis.

M F Hofer1, M R Lester, P M Schlievert, D Y Leung.   

Abstract

BACKGROUND: Atopic dermatitis (AD) is a chronic skin disease associated with increased IgE synthesis and colonization with Staphylococcus aureus secreting exotoxins, such as Toxic Shock Syndrome Toxin-1 (TSST-1).
OBJECTIVES: In this study, we were interested in determining the in vitro effects of TSST-1 on IgE synthesis in peripheral blood mononuclear cells from patients with AD.
METHODS: We stimulated peripheral blood mononuclear cells (PBMC) from AD patients with a wide range of TSST-1 concentrations and measured IgE synthesis by enzyme-linked immunosorbent assay (ELISA) after 14 days.
RESULTS: We show herein that TSST-1 produced antagonistic effects on IgE synthesis by PBMC from AD patients, depending on the concentration used: IgE synthesis was inhibited at 1000 pg/mL (P < 0.05) and enhanced at 0.01 pg/mL (P < 0.01) of toxin. TSST-1 was found to induce the production of much higher amounts of interferon-gamma (IFN gamma) at 1000 pg/mL than at 0.01 pg/mL of toxin (P = 0.0001). More importantly, immunoglobulin E (IgE) synthesis was enhanced by TSST-1 at 1 pg/mL in the presence of antibodies blocking IFN gamma activity. The other immunoglobulin (Ig) isotypes were also increased after TSST-1 stimulation suggesting that the enhanced IgE synthesis was secondary to a polyclonal B cell activation rather than an isotype switch. TSST-1-stimulated IgE synthesis was T cell-dependent because purified tonsil B cells were only able to synthesize increased amounts of IgE when small numbers of T cells were added to the cultures. Anti-HLA-DR and anti-LFA-1 monoclonal antibodies (MoAb) inhibited TSST-1-enhanced IgE synthesis, suggesting that the bridging of the T cell receptor (TCR) and major histocompatibility complex (MHC) class II on B cells was necessary for activation of B cell differentiation.
CONCLUSION: These data indicate that staphylococcal superantigens are able, at concentrations inducing low amounts of IFN gamma, to stimulate IgE synthesis by PBMC from AD patients, and suggest that staphylococcal toxins may contribute to elevated IgE synthesis in AD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8821303     DOI: 10.1111/j.1365-2222.1995.tb03046.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  6 in total

Review 1.  Staphylococcus aureus superantigens and airway disease.

Authors:  Claus Bachert; Philippe Gevaert; Paul van Cauwenberge
Journal:  Curr Allergy Asthma Rep       Date:  2002-05       Impact factor: 4.806

2.  Pyrogenicity and cytokine-inducing properties of Streptococcus pyogenes superantigens: comparative study of streptococcal mitogenic exotoxin Z and pyrogenic exotoxin A.

Authors:  H Müller-Alouf; T Proft; T M Zollner; D Gerlach; E Champagne; P Desreumaux; C Fitting; C Geoffroy-Fauvet; J E Alouf; J M Cavaillon
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

3.  Rhinosinusitis and asthma: a link for asthma severity.

Authors:  C Bachert; S E M Claeys; P Tomassen; T van Zele; N Zhang
Journal:  Curr Allergy Asthma Rep       Date:  2010-05       Impact factor: 4.806

4.  Children with atopic dermatitis who carry toxin-positive Staphylococcus aureus strains have an expansion of blood CD5- B lymphocytes without an increase in disease severity.

Authors:  P D Arkwright; B D Cookson; M R Haeney; D Sanyal; M R Potter; T J David
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

Review 5.  Pathophysiology of chronic rhinosinusitis, pharmaceutical therapy options.

Authors:  Claus Bachert; Gabriële Holtappels
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2015-12-22

Review 6.  Superantigens and nasal polyps.

Authors:  Claus Bachert; Thibaut van Zele; Philippe Gevaert; Lore De Schrijver; Paul Van Cauwenberge
Journal:  Curr Allergy Asthma Rep       Date:  2003-11       Impact factor: 4.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.